Biocartis

Biocartis completes $44.5M series D funding

Friday, December 14, 2012

Biocartis, a molecular diagnostics company developing and commercializing high quality, easy to use platforms and clinically relevant oncology assays, has completed a $44.5 million Series D equity funding entirely backed by existing investors.

[Read More]